Diseases, Conditions, Syndromes

Study looks at treatment patterns for alopecia areata

For patients with alopecia areata (AA), corticosteroids are the most commonly used treatment, and by one year, 71.8 percent are receiving no treatment, according to a study published online Sept. 20 in JAMA Dermatology.

Medications

FDA approves Litfulo for teens, adults with alopecia areata

The U.S. Food and Drug Administration has approved Litfulo (ritlecitinib) for adults and adolescents aged 12 years and older with severe alopecia areata at a recommended dose of 50 mg. Approval of Litfulo was granted to Pfizer.

Immunology

Psoriasis tied to elevated risk for celiac disease

Individuals with psoriasis have double the odds of having celiac disease (CD) versus individuals without psoriasis, according to a research letter published online Feb. 9 in the Journal of the American Academy of Dermatology.

Diseases, Conditions, Syndromes

Treatments explored for moderate-to-severe alopecia areata

(HealthDay)—For patients with alopecia areata (AA), treatment with an inhibitor of janus kinase (JAK)3 and the tyrosine kinase expressed in the hepatocellular carcinoma kinase family, ritlecitinib, and an inhibitor of tyrosine ...

Diseases, Conditions, Syndromes

Androgenetic alopecia may reduce health-related quality of life

(HealthDay)—Androgenetic alopecia is associated with moderate impairment of health-related quality of life (HRQOL) and emotions, according to a review published online July 7 in JAMA Dermatology.

page 2 from 4